Figure 1. Pirfenidone remodels the tumor microenvironment by reducing collagen and hyaluronan levels in a dose-depended manner.

(A–D) Representative immunofluorescent images from whole tumor samples of control and Pirfenidone-treated tumors for collagen, hyaluronan (HA), CD31 and lectin. (E, F) Area fraction analysis shows that 500 and 650 mg/kg Pirfenidone reduces collagen and hyaluronan levels significantly compared to the control group. (G–I) The 500 and 650 mg/kg dose of Pirfenidone increased significantly mean vessel diameter, improving fraction of perfused vessels but had no effect on number of tumor blood vessels (n = 6–8). Asterisks indicate a statistically significant difference between compared groups (p < 0.05). Scale bar: 100 μm.